{"transactions":[{"id":686919,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:30:03.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":73240,"derivative":{"exercise_price":18.17,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001778623-26-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000009/ownership.xml","form_type":"4"}},{"id":686918,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-14T20:30:03.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":18.17,"value":272550.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001778623-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000009/ownership.xml","form_type":"4"}},{"id":690759,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":16167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":16167},"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690758,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":76167,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":3833},"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690757,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":16167,"price":110.38,"value":1784513.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $110.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690756,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":16167,"price":17.88,"value":289065.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":16167,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690755,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":616,"price":111.18,"value":68486.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.08 to $111.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690754,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":3217,"price":110.61,"value":355832.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.07 to $111.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":616,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":690753,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-08-11T21:08:31.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":3833,"price":17.88,"value":68534.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":3833,"source":{"system":"sec-edgar","filing":"0001778623-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000007/ownership.xml","form_type":"4"}},{"id":732100,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732099,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":13229,"price":81.38,"value":1076576.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732098,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":16771,"price":80.34,"value":1347382.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":13229,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":732097,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2026-06-18T20:30:09.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":17.88,"value":536400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001778623-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000005/ownership.xml","form_type":"4"}},{"id":919420,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T22:41:33.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":52.46,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001778623-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000177862326000002/ownership.xml","form_type":"4"}},{"id":1284870,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:23:32.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":22.07,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-013488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025013488/ownership.xml","form_type":"4"}},{"id":1500442,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T00:05:16.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-065566","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024065566/ownership.xml","form_type":"4"}},{"id":1669542,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T21:46:18.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":17.88,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000950170-24-007994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024007994/ownership.xml","form_type":"4"}},{"id":2028424,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T16:14:46.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":96100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date."}],"balance_after":96100,"derivative":{"exercise_price":1.69,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":96100},"source":{"system":"sec-edgar","filing":"0001209191-23-007500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123007500/doc4.xml","form_type":"4"}},{"id":2282305,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-04T16:22:07.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":177000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest as to 25% on April 25, 2023, and 2.083% in 36 monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date."}],"balance_after":177000,"derivative":{"exercise_price":2.35,"expiration_date":"2032-04-25","underlying":"Common Stock","underlying_shares":177000},"source":{"system":"sec-edgar","filing":"0001209191-22-027079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122027079/doc4.xml","form_type":"4"}},{"id":2500492,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":18806},"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2500491,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":24334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":24334},"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2500490,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":8500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2500489,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2500488,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":6700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.37,"underlying":"Common Stock","underlying_shares":6700},"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2500487,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-11-22T09:05:46.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":23423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142271","document":"tm2133601-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142271/tm2133601-5_4seq1.xml","form_type":"4"}},{"id":2514718,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-12T16:15:31.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vested as to 25% of the shares on July 14, 2015 and the remaining shares vested in equal quarterly installments over the following three years thereafter."}],"balance_after":0,"derivative":{"exercise_price":29.37,"expiration_date":"2024-08-01","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-010095","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021010095/edgar.xml","form_type":"4"}},{"id":2514717,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-11-12T16:15:31.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":4500,"price":29.37,"value":132165.0,"ownership":{"direct":true},"balance_after":23423,"source":{"system":"sec-edgar","filing":"0001179110-21-010095","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021010095/edgar.xml","form_type":"4"}},{"id":2561835,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-22T18:08:28.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":1450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":41.2,"expiration_date":"2025-01-08","underlying":"Common Stock","underlying_shares":1450},"source":{"system":"sec-edgar","filing":"0001179110-21-008895","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008895/edgar.xml","form_type":"4"}},{"id":2561834,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-22T18:08:28.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001179110-21-008895","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008895/edgar.xml","form_type":"4"}},{"id":2561833,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-22T18:08:28.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":6650,"price":150.05,"value":997832.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":18923,"source":{"system":"sec-edgar","filing":"0001179110-21-008895","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008895/edgar.xml","form_type":"4"}},{"id":2561832,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-22T18:08:28.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":1450,"price":41.2,"value":59740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":25573,"source":{"system":"sec-edgar","filing":"0001179110-21-008895","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008895/edgar.xml","form_type":"4"}},{"id":2561831,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-22T18:08:28.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":5200,"price":30.17,"value":156884.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":24123,"source":{"system":"sec-edgar","filing":"0001179110-21-008895","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008895/edgar.xml","form_type":"4"}},{"id":2574584,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-09T17:07:38.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":1407,"price":130,"value":182910.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18923,"source":{"system":"sec-edgar","filing":"0001179110-21-008690","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008690/edgar.xml","form_type":"4"}},{"id":2574583,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-09T17:07:38.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":6,"price":130,"value":780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20330,"source":{"system":"sec-edgar","filing":"0001179110-21-008690","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008690/edgar.xml","form_type":"4"}},{"id":2574582,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-09-09T17:07:38.000Z","date":"2021-09-07","kind":"tax_withholding","acquired":false,"shares":587,"price":129.36,"value":75934.32,"ownership":{"direct":true},"balance_after":20336,"source":{"system":"sec-edgar","filing":"0001179110-21-008690","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008690/edgar.xml","form_type":"4"}},{"id":2677302,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-06-08T18:53:04.000Z","date":"2021-06-07","kind":"tax_withholding","acquired":false,"shares":108,"price":126.69,"value":13682.52,"ownership":{"direct":true},"balance_after":20923,"source":{"system":"sec-edgar","filing":"0001179110-21-006496","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021006496/edgar.xml","form_type":"4"}},{"id":2885166,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T19:50:42.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":18806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2021."}],"balance_after":18806,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":18806},"source":{"system":"sec-edgar","filing":"0001179110-21-001125","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001125/edgar.xml","form_type":"4"}},{"id":2885165,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-02-02T19:50:42.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":4868,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21031,"source":{"system":"sec-edgar","filing":"0001179110-21-001125","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001125/edgar.xml","form_type":"4"}},{"id":2915158,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-01-06T19:12:01.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":100,"price":124.3,"value":12430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":16163,"source":{"system":"sec-edgar","filing":"0001179110-21-000373","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000373/edgar.xml","form_type":"4"}},{"id":2915157,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-01-06T19:12:01.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":56,"price":122.93,"value":6884.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":16263,"source":{"system":"sec-edgar","filing":"0001179110-21-000373","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000373/edgar.xml","form_type":"4"}},{"id":2915156,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-01-06T19:12:01.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":1900,"price":122.46,"value":232674.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.86 to $122.85 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":16319,"source":{"system":"sec-edgar","filing":"0001179110-21-000373","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000373/edgar.xml","form_type":"4"}},{"id":2915155,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2021-01-06T19:12:01.000Z","date":"2021-01-04","kind":"tax_withholding","acquired":false,"shares":942,"price":124.31,"value":117100.02,"ownership":{"direct":true},"balance_after":18219,"source":{"system":"sec-edgar","filing":"0001179110-21-000373","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000373/edgar.xml","form_type":"4"}},{"id":3035270,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-09-09T17:49:27.000Z","date":"2020-09-08","kind":"sale","acquired":false,"shares":929,"price":89.85,"value":83470.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.68 to $90.28 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":19161,"source":{"system":"sec-edgar","filing":"0001179110-20-009643","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020009643/edgar.xml","form_type":"4"}},{"id":3035269,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-09-09T17:49:27.000Z","date":"2020-09-08","kind":"sale","acquired":false,"shares":1071,"price":89.2,"value":95533.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.63 to $89.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":20090,"source":{"system":"sec-edgar","filing":"0001179110-20-009643","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020009643/edgar.xml","form_type":"4"}},{"id":3178456,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":27.97,"expiration_date":"2026-03-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178455,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":417,"price":87.53,"value":36500.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.39 to $87.60 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4."}],"balance_after":21161,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178454,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":1100,"price":86.69,"value":95359.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.35 to $87.29 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":21578,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178453,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":2883,"price":85.77,"value":247274.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.30 to $86.11 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":22678,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178452,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":700,"price":84.62,"value":59234.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.18 to $85.12 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":25561,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178451,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":900,"price":83.49,"value":75141.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.95 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":26261,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3178450,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-04-10T17:30:39.000Z","date":"2020-04-08","kind":"exercise","acquired":true,"shares":6000,"price":27.97,"value":167820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":27161,"source":{"system":"sec-edgar","filing":"0001179110-20-004830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020004830/edgar.xml","form_type":"4"}},{"id":3302763,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-24T17:33:56.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":24334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2020."}],"balance_after":24334,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":24334},"source":{"system":"sec-edgar","filing":"0001179110-20-000771","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000771/edgar.xml","form_type":"4"}},{"id":3302762,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-01-24T17:33:56.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":6369,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21161,"source":{"system":"sec-edgar","filing":"0001179110-20-000771","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000771/edgar.xml","form_type":"4"}},{"id":3322377,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-01-03T21:51:17.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":875,"price":51.23,"value":44826.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.87 to $51.74 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":14792,"source":{"system":"sec-edgar","filing":"0001179110-20-000278","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000278/edgar.xml","form_type":"4"}},{"id":3322376,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2020-01-03T21:51:17.000Z","date":"2020-01-02","kind":"sale","acquired":false,"shares":434,"price":52.83,"value":22928.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":15667,"source":{"system":"sec-edgar","filing":"0001179110-20-000278","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000278/edgar.xml","form_type":"4"}},{"id":3418448,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2019-09-10T20:25:34.000Z","date":"2019-09-10","kind":"sale","acquired":false,"shares":23,"price":45.75,"value":1052.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.74 to $45.78 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":16101,"source":{"system":"sec-edgar","filing":"0001179110-19-010223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019010223/edgar.xml","form_type":"4"}},{"id":3418447,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2019-09-10T20:25:34.000Z","date":"2019-09-10","kind":"sale","acquired":false,"shares":801,"price":45.18,"value":36189.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.68 to $45.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":16124,"source":{"system":"sec-edgar","filing":"0001179110-19-010223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019010223/edgar.xml","form_type":"4"}},{"id":3440902,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2019-08-12T16:18:20.000Z","date":"2019-08-09","kind":"sale","acquired":false,"shares":3268,"price":45,"value":147060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":16925,"source":{"system":"sec-edgar","filing":"0001179110-19-009377","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019009377/edgar.xml","form_type":"4"}},{"id":3459748,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2019-07-17T17:49:51.000Z","date":"2019-07-16","kind":"sale","acquired":false,"shares":538,"price":40.71,"value":21901.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.64 to $41.00 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":20193,"source":{"system":"sec-edgar","filing":"0001179110-19-008707","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019008707/edgar.xml","form_type":"4"}},{"id":3496939,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Option to Purchase Common Stock","published_at":"2019-06-07T16:39:56.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":6700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the first four years after the grant."}],"balance_after":6700,"derivative":{"exercise_price":40.37,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":6700},"source":{"system":"sec-edgar","filing":"0001179110-19-007353","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019007353/edgar.xml","form_type":"4"}},{"id":3496938,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23341,"kind":"person","name":"Veness Adam M","position":1,"cik":"0001778623","reported_name":"Veness Adam M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel and Sec."}}],"security":"Common Stock","published_at":"2019-06-07T16:39:56.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20731,"source":{"system":"sec-edgar","filing":"0001179110-19-007353","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019007353/edgar.xml","form_type":"4"}}]}